It's so helpful that Illumina put it's cluster density numbers up without telling anyone how many square millimeters a miseq flowcell has. Does anyone know the magic number?
-
-
they said 3.5-5million clusters totalComment
-
Huh, must have missed that.Comment
-
There is also a PowerPoint presentation in PDF format on the Illumina site which gives more infomration on the poster.
One interesting thing is the error plots for all runs they show. Something I have not noticed before (need to look next week) is that all the plots show a kind of step-like profile increase in quality over the first 20 or so bases. Then there is a drop off in quality as run length increases. However this is not a simple drop as shown on slide 14.
Slide 18 shows HiSeq v MiSeq for 100bp runs of an E. coli library. Both show a drop in quality at about which recovers immediatley after, however it is at 75/65bp for Hi/MiSeq respectively. This may be an error in the library???
Slide 5 shows some lovely data on amplicon resequencing and mutation detection. It makes me wonder what the final reports are going to look like when this gets into a non-bioinformaticians hands?Comment
-
Just found this hilarious videos about MYSEQ and HISEQ
Comment
-
Custom sequencing primers in MiSeq?
We have a barcoded/indexed library that requires custom sequencing primers to run on Illumina. Custom sequencing primers prevent sharing lanes with other projects. Perhaps Miseq could be an option since it is possible to use entire flowcell. Illumina webinar "my samples, my study, myseq" mentions @22nd minute about sample loading but does not say anything about custom primers:
Can we use custom sequencing primers in MiSeq?Comment
-
I think this service will be provided via GoldenGate platform.Comment
-
MiSeq service
Who has these machines? How can I locate a collaborator having one? Preferably around southeast US.Comment
-
Given that GoldenGate is a technology upstream of their arrays, could you expand on how this is going to be applied to sequencing?Comment
-
The Illumina GoldenGate PCR is used for lower plex genotyping and other applications on arrays. The PCR is likely to be modified such that a set of locus specific primers have regions with complimentarity to Illumina adapters. GoldenGate on arrays allows up to 3072 multiplex reactions. This offers the possibility of 96-384 and even up to 3072 loci (e.g. exons) being targeted by PCR in a standard 96 or 384 well plate from very low input DNA. And generating sequence ready amplicons which would fit neatly into a MiSeq PE run. The whole workflow including PCR could be completed in one day with results returned, analysed the next morning depending on run configuration.
This workflow would compete with other targeting approaches aimed at low multiplexing and not with whole exome resequencing for instance. As it could be 96 or 384 well based I could see a panel of cancer genes being resequenced at every exon as a standard product any user could buy from Illumina, add their samples to and get results on really quickly. In fact I've asked to do exactly that. The GoldenGate product was announced as being launched at the same time as MiSeq in September/October.Comment
-
The Illumina GoldenGate PCR is used for lower plex genotyping and other applications on arrays. The PCR is likely to be modified such that a set of locus specific primers have regions with complimentarity to Illumina adapters. GoldenGate on arrays allows up to 3072 multiplex reactions. This offers the possibility of 96-384 and even up to 3072 loci (e.g. exons) being targeted by PCR in a standard 96 or 384 well plate from very low input DNA. And generating sequence ready amplicons which would fit neatly into a MiSeq PE run. The whole workflow including PCR could be completed in one day with results returned, analysed the next morning depending on run configuration.
This workflow would compete with other targeting approaches aimed at low multiplexing and not with whole exome resequencing for instance. As it could be 96 or 384 well based I could see a panel of cancer genes being resequenced at every exon as a standard product any user could buy from Illumina, add their samples to and get results on really quickly.
In fact I've asked to do exactly that. The GoldenGate product was announced as being launched at the same time as MiSeq in September/October.Comment
-
GW_OK here is an answer from my measurements.
A MiSeq flowcell is 1.5x23mm see a picture here… Core-Genomics blog, however only a portion of this is imaged as far as I am aware.Comment
-
Like James explained, Goldengate is a large platform which includes several technologies like primer design. This platform is also shared and used on other technologies from illumina, for example BeadXpress if I'm not wrong.Originally posted by krobison View PostComment
-
MiSeq vs IT - the latest
Illumina makes a strong statement regarding MiSeq and Ion Torrent data quality...
Comment
-
In addition to Illumina's analysis, there are analyses from Ion (referenced in my blog item) and from Edge Bio (which provides Ion as a service).Comment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM
Comment